Royalty Pharma PLC (NAS:RPRX)
$ 26.6 0.31 (1.18%) Market Cap: 11.82 Bil Enterprise Value: 17.66 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 79/100

Royalty Pharma PLC at Bank of America NAPA Healthcare Conference Transcript

Jun 15, 2021 / 05:30PM GMT
Release Date Price: $44.02 (-1.34%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Okay. Welcome to the second day of the BofA Virtual Napa Conference. We really do wish this was actual Napa. This is our second annual virtual Napa, which is -- which I'd rather be there, but that's okay.

My name is Geoff Meacham. I'm the senior biopharma analyst. We have Bill Maughan from my team as well. And we're thrilled to have Royalty Pharma with us today and we have 3 executives from left to right, Terrance Coyne, Chief Financial Officer. We have Chris Hite, Executive VP and Vice Chairman; and Jim Reddoch, Executive VP, Co-Head of Research and Chief Scientific Officer. Guys, welcome.

Terrance Coyne
Royalty Pharma plc - Executive VP & CFO

Geoff, great to be here. Thanks for having us.

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Yes, of course. So Terry, maybe just kick it over to you to give kind of a high-level background to Royalty Pharma. We have a lot of questions here

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot